Landmark map of human brain’s gene activity holds clues to Alzheimer’s disease and more

Scientists have assembled a population-scale view of the human brain’s regulatory landscape. The research draws on sequencing data from more than 6.3 million individual cells collected from nearly 1,500 post-mortem human brains, providing resolution into the cellular anatomy of the prefrontal cortex.

The findings, published in a collection of eight studies including three papers in Nature, span donations from infants up to an individual aged 108. The cohorts encompass both neurotypical controls and people diagnosed with eight distinct psychiatric and neurodegenerative conditions, creating a comparative matrix for brain disease research.

Consortium Origins and Focus on the Prefrontal Cortex

The map represents the culmination of an initiative that began in 2019 under the PsychAD Consortium, an NIH-funded partnership uniting multiple US institutions. The collaborative effort was designed to connect genetic variation, aging, and disease to functional changes within specific brain cell populations.

Investigators concentrated their efforts on the prefrontal cortex because of its central role in working memory and executive functions, including planning, focusing, and multitasking. Disruptions within a specific subregion known as the dorsolateral prefrontal cortex are implicated in multiple psychiatric disorders and various forms of dementia.

External specialists note that previous investigations were largely constrained by sample sizes. Single-cell studies of the human brain have traditionally been limited to relatively small numbers of individuals, Miao explained. Pushing us into a population-scale setting changes the kinds of questions we can ask.

Tissue Sources and Harmonized Clinical Metadata

Building the resource required harmonizing clinical, pathological, and demographic metadata across multiple distinct tissue repositories and prospective studies. Brain specimens were sourced from two primary brain banks: the Mount Sinai NIH Neurobiobank (MSSM), which contributed 1,042 samples, and the NIMH-IRP Human Brain Collection Core (HBCC), which provided 300 samples. An additional 152 samples were drawn from five prospective cohort studies conducted at the Rush Alzheimer’s Disease Center (RADC).

• Neuritic Plaque Density: Harmonized using the CERAD scoring scheme ranging from 1 (normal brain with no neuritic plaque) to 4 (frequent plaque indicating definite Alzheimer’s disease).
• Cognitive Impairment: Evaluated using a three-level ordinal scale categorized into no cognitive impairment, minor cognitive impairment, and definite clinical dementia, bridging the Clinical Dementia Rating scale used by MSSM with the consensus diagnoses from RADC.
• Neurofibrillary Tangle Pathology: Measured via the Braak staging score, where 0 represents normal asymptomatic tissue and 5 through 6 indicate that NFTs are widespread, affecting multiple cortical regions.

The donors spanned diverse genetic ancestries. Where genotypic data was unavailable, researchers leveraged quadratic discriminant analysis trained on the 1000 Genomes Project alongside race and ethnicity variables as proxies to retain sample depth.

Lifespan Development and Transcriptomic Vulnerability

To establish a baseline for pathology, a foundational study analyzed healthy brains collected from individuals ranging from under one year old to 97 years of age. The analysis revealed three distinct phases of cortical development: a rapid remodeling phase during early life, stability through the mid-life period starting at age 24, and a secondary remodeling phase initiating around age 65.

Different cellular compartments—including neurons, immune cells, and vascular cells—displayed distinct gene activity shifts across these developmental epochs. Late-life changes prominently involved cell types associated with immune activity, stress responses, and circadian regulation.

The overarching dataset encompasses eight specific brain disorders: Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, vascular dementia, tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder. By analyzing these conditions against control tissue, researchers mapped how transcriptomic vulnerability varies across disorders within the same anatomical hub.

Despite the breadth of the current map, consortium leaders emphasize that the prefrontal cortex represents only a single piece of the neurological puzzle. This is an important window into brain disease, but additional regions will be needed to understand the full picture, Roussos noted.